INT165490

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.45
First Reported 2008
Last Reported 2010
Negated 1
Speculated 1
Reported most in Body
Documents 8
Total Number 21
Disease Relevance 15.31
Pain Relevance 5.05

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

signal transduction (Lpar1) plasma membrane (Lpar1) cytoplasm (Lpar1)
signal transducer activity (Lpar1)
Anatomy Link Frequency
dorsal root 1
spinal 1
lymphocyte 1
nerve 1
peripheral nerve 1
Lpar1 (Mus musculus)
Pain Link Frequency Relevance Heat
Demyelination 220 100.00 Very High Very High Very High
Neuropathic pain 209 99.88 Very High Very High Very High
Hyperalgesia 13 99.72 Very High Very High Very High
Sciatic nerve 105 99.70 Very High Very High Very High
c fibre 45 98.00 Very High Very High Very High
Peripheral nerve injury 10 97.52 Very High Very High Very High
Inflammation 20 96.24 Very High Very High Very High
fibrosis 119 95.76 Very High Very High Very High
allodynia 70 95.24 Very High Very High Very High
Potency 41 94.56 High High
Disease Link Frequency Relevance Heat
Demyelinating Disease 259 100.00 Very High Very High Very High
Neuropathic Pain 300 99.88 Very High Very High Very High
Ovarian Cancer 211 99.84 Very High Very High Very High
Nervous System Injury 98 99.84 Very High Very High Very High
Reprotox - General 1 13 99.84 Very High Very High Very High
Hyperalgesia 20 99.72 Very High Very High Very High
Pathologic Neovascularization 13 99.28 Very High Very High Very High
Nociception 70 99.18 Very High Very High Very High
Disease 98 98.32 Very High Very High Very High
Metastasis 187 98.16 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
LPA1 receptor-dependent damage of Remak bundles
Regulation (dependent) of LPA1 receptor
1) Confidence 0.45 Published 2010 Journal Mol Pain Section Body Doc Link PMC2989310 Disease Relevance 1.20 Pain Relevance 0.79
In the present study, we further examined the involvement of LPA1 receptor signaling in the spinal reorganization through A?
Spec (examined) Regulation (involvement) of LPA1 in spinal
2) Confidence 0.45 Published 2008 Journal Mol Pain Section Body Doc Link PMC2599895 Disease Relevance 1.36 Pain Relevance 0.73
LPA receptors and LPA receptor gene expression activates Rho in peripheral nerves [69-71], which suggests that LPA receptors might pathophysiologically activate Rho in neuropathic pain states of peripheral nerve injury.
Regulation (receptors) of LPA in peripheral nerve associated with nervous system injury, neuropathic pain and peripheral nerve injury
3) Confidence 0.44 Published 2008 Journal Mol Pain Section Body Doc Link PMC2365930 Disease Relevance 1.26 Pain Relevance 0.92
LPA receptors of the EDG family are dysregulated in ovarian cancer.
Regulation (dysregulated) of LPA associated with ovarian cancer
4) Confidence 0.40 Published 2010 Journal British Journal of Pharmacology Section Body Doc Link PMC2989581 Disease Relevance 1.50 Pain Relevance 0.12
In the present study, we demonstrated that the sciatic nerve injury caused LPA1 receptor-mediated demyelination and its underlying MAG down-regulation only in the dorsal root, but not spinal nerve or sciatic nerve (Figures 1, 2, 4).
Regulation (regulation) of LPA1 receptor in dorsal root associated with demyelination, nervous system injury and sciatic nerve
5) Confidence 0.39 Published 2010 Journal Mol Pain Section Body Doc Link PMC2989310 Disease Relevance 1.15 Pain Relevance 0.69
From the fact that the basal nociceptive thresholds in behavioral tests were not affected in Lpar1-/- mice [10,11], it is evident that LPA1 receptor signaling works only after occurrence of the nerve-injury.
Neg (not) Regulation (affected) of Lpar1 in nerve associated with nociception and injury
6) Confidence 0.39 Published 2008 Journal Mol Pain Section Body Doc Link PMC2599895 Disease Relevance 1.37 Pain Relevance 0.74
Altogether, our results suggested that targeting autotaxin/LPA track might contribute to the development of new therapies to improve the care of patients with osteophylic solid tumors.


Regulation (targeting) of LPA associated with solid tumor
7) Confidence 0.37 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2840030 Disease Relevance 1.51 Pain Relevance 0
It seems that there are two types of LPA receptors that regulate LPA responsiveness in human platelets.
Regulation (regulate) of LPA in platelets
8) Confidence 0.35 Published 2010 Journal British Journal of Pharmacology Section Body Doc Link PMC2989581 Disease Relevance 0.34 Pain Relevance 0.03
While the opportunity to control LPA-mediated pathophysiologies is apparent, harnessing the LPA system through pharmacological tools remains a stimulating task for the academic community and a lucrative opportunity for the pharmaceutical industry.



Regulation (control) of LPA
9) Confidence 0.26 Published 2010 Journal British Journal of Pharmacology Section Body Doc Link PMC2989581 Disease Relevance 0.32 Pain Relevance 0.04
This has further provided valuable proof-of-concept data to support LPA receptors and LPA metabolic enzymes as targets for the treatment of medically important diseases that include neuropsychiatric disorders, neuropathic pain, infertility, cardiovascular disease, inflammation, fibrosis, and cancer.
Regulation (targets) of LPA associated with fibrosis, reprotox - general 3, inflammation, cancer, cardiovascular disease, neuropathic pain and disease
10) Confidence 0.24 Published 2010 Journal Annu. Rev. Pharmacol. Toxicol. Section Abstract Doc Link 20055701 Disease Relevance 0.76 Pain Relevance 0.19
This has further provided valuable proof-of-concept data to support LPA receptors and LPA metabolic enzymes as targets for the treatment of medically important diseases that include neuropsychiatric disorders, neuropathic pain, infertility, cardiovascular disease, inflammation, fibrosis, and cancer.
Regulation (targets) of LPA associated with fibrosis, reprotox - general 3, inflammation, cancer, cardiovascular disease, neuropathic pain and disease
11) Confidence 0.21 Published 2010 Journal Annu. Rev. Pharmacol. Toxicol. Section Abstract Doc Link 20055701 Disease Relevance 0.75 Pain Relevance 0.19
There is a wealth of evidence that links LPA, LPA3 and LPA1 to the regulation of prostate cancer cells (Qi et al., 1998; Prenzel et al., 1999; Im et al., 2000; Daaka, 2002; Guo et al., 2006; Hwang et al., 2006).
Regulation (regulation) of LPA1 associated with reprotox - general 1
12) Confidence 0.18 Published 2010 Journal British Journal of Pharmacology Section Body Doc Link PMC2989581 Disease Relevance 0.77 Pain Relevance 0.10
LPA production and the LPA receptor subtypes expressed by different subsets of blood cells and cells of the vessel wall are undoubtedly important potential drug targets for manipulating pathological angiogenesis and thrombosis.


Regulation (targets) of LPA receptor in blood cells associated with pathologic neovascularization and thrombosis
13) Confidence 0.18 Published 2010 Journal British Journal of Pharmacology Section Body Doc Link PMC2989581 Disease Relevance 0.80 Pain Relevance 0.14
The LPA GPCR are the most studied and best understood targets of LPA.
Regulation (targets) of LPA
14) Confidence 0.18 Published 2010 Journal British Journal of Pharmacology Section Body Doc Link PMC2989581 Disease Relevance 0.08 Pain Relevance 0.04
The field still lacks drug-like compounds with the desired specificity or ubiquity for LPA targets.
Regulation (targets) of LPA
15) Confidence 0.15 Published 2010 Journal British Journal of Pharmacology Section Body Doc Link PMC2989581 Disease Relevance 0.41 Pain Relevance 0.05
The LPA GPCR are the most studied and best understood targets of LPA.
Regulation (targets) of LPA
16) Confidence 0.15 Published 2010 Journal British Journal of Pharmacology Section Body Doc Link PMC2989581 Disease Relevance 0.08 Pain Relevance 0.04
Many of us are now convinced that therapies targeting LPA biosynthesis and signalling are feasible for the treatment of devastating human diseases such as cancer, fibrosis and degenerative conditions.
Regulation (targeting) of LPA associated with fibrosis, cancer and disease
17) Confidence 0.15 Published 2010 Journal British Journal of Pharmacology Section Abstract Doc Link PMC2989581 Disease Relevance 0.55 Pain Relevance 0.05
, an intracellular target of LPA that is exclusively activated by unsaturated acyl species of LPA (Tsukahara et al., 2006).
Regulation (target) of LPA
18) Confidence 0.15 Published 2010 Journal British Journal of Pharmacology Section Body Doc Link PMC2989581 Disease Relevance 0 Pain Relevance 0.05
In addition, there are several enzymes that utilize LPA as a substrate or generate it as a product and are under its regulatory control.
Regulation (utilize) of LPA
19) Confidence 0.15 Published 2010 Journal British Journal of Pharmacology Section Abstract Doc Link PMC2989581 Disease Relevance 0.23 Pain Relevance 0
These observations combined with the role of S1P in lymphocyte egress underscore the importance of lysophospholipids in lymphocyte trafficking and assign LPA and S1P to distinct steps, homing and egress respectively.
Regulation (importance) of LPA in lymphocyte
20) Confidence 0.07 Published 2010 Journal British Journal of Pharmacology Section Body Doc Link PMC2989581 Disease Relevance 0.12 Pain Relevance 0.03

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox